Aventis Warrant Proposal Rejected By France; Sanofi Considers Raising Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
AMF decision clears one hurdle in path of Sanofi/Aventis merger, but Sanofi still needs to decide whether to sweeten its bid.
You may also be interested in...
Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Sanofi's winning bid for Aventis includes an added $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
Sanofi Holds Line On Aventis Merger Price; Novartis Enters Talks
Sanofi will continue to evaluate the market reaction before deciding whether to sweeten its bid. Novartis accepts Aventis’ invitation to explore a deal; the move indicates France has expressed neutrality on an Aventis/Novartis combination.
Aventis Offers Plan To Protect Shareholders From Sanofi Plavix Patent Risk
The Aventis board also votes to enter into negotiations with Novartis, thereby satisfying one of Novartis’ two prerequisites for commencing merger talks. Aventis will “pursue discussions” with French and German authorities to address their concerns about an Aventis/Novartis deal.